Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113833 | 0.88 | EBP (0.73) | EBPSIGMAR1HRH3ESR1ESR2 | |
| SCHEMBL3772076 | 0.86 | EBP (0.79) | EBPSIGMAR1HRH3PTPN1ESR1 | |
| SCHEMBL5713216 | 0.77 | EBP (0.57) | EBPSIGMAR1HRH3ESR1ESR2 | |
| SCHEMBL7213535 | 0.76 | EBP (0.76) | EBPSIGMAR1HRH3ESR1ESR2 | |
| SCHEMBL2180695 | 0.75 | EBP (0.60) | EBPSIGMAR1HRH3ESR1ESR2 | |
| SCHEMBL8015672 | 0.75 | EBP (0.88) | EBPSIGMAR1HRH3ESR1ESR2 | |
| Nafoxidine SCHEMBL10563464 | 0.73 | EBP (1.00) | EBPSIGMAR1HRH3ESR1ESR2 | |
| Nafoxidine SCHEMBL153125 | 0.73 | EBP (1.00) | EBPSIGMAR1HRH3ESR1ESR2 | |
| Nafoxidine SCHEMBL29494604 | 0.73 | EBP (1.00) | EBPSIGMAR1HRH3ESR1ESR2 | |
| Nafoxidine SCHEMBL115778 | 0.73 | EBP (0.98) | EBPSIGMAR1HRH3ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | CAMERON KIMBERLY O | 2010-12-16 | — | — | US | disclosed |
| US-RE39558-E1 | 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1411049-A1 | Estrogen Agonists/Antagonists | PFIZER INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20020132816-A1 | Estrogen agonists/antagonists for preventing breast cancer | CAMERON KIMBERLY O (US) | 2002-09-19 | — | — | US | disclosed |
| US-6441193-B1 | INTERMEDIATES SUCH AS 1-(2-(4-(6-METHOXY-3,4-DIHYDRONAPHTHA-LEN-1-YL)PHENOXY)ETHYL)PYRROLIDINE AND COMPOUNDS SUCH AS CIS-6-PHENYL-5-(4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL)-5,6,7,8 -TETRAHYDRONAPHTHALEN-2-OL, HYDROBROMIDE SALT | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0802910-B1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1151998-A1 | Estrogen agonists/antagonists | PFIZER INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010025051-A1 | Estrogen agonists/antagonists for preventing breast cancer | CAMERON KIMBERLY O (US) | 2001-09-27 | — | — | US | disclosed |
| US-6204286-B1 | 8-(P-(PYRROLIDINYLALKOXY)PHENYL)TETRAHYDRONAPHTHOLS | PFIZER INC | 2001-03-20 | — | — | US | disclosed |
| US-6153622-A | Estrogen agonists/antagonists | PFIZER, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-1004306-A2 | Estrogen agonists/antagonists | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0802910-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER INC. (US) | 1997-10-29 | — | — | EP | disclosed |
| US-5552412-A | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis | PFIZER INC (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025051-A1 | Estrogen agonists/antagonists for preventing breast cancer | GPER1, ESR1, BRCA1 | EBP 65/4885SIGMAR1 372/4885HRH3 3175/4885 |
| US-20100317712-A1 | Estrogen Agonists/Antagonists For Preventing Breast Cancer | ESR1, GPER1, ESR2 | EBP 42/4885SIGMAR1 606/4885HRH3 2730/4885 |
| US-20020132816-A1 | Estrogen agonists/antagonists for preventing breast cancer | GPER1, ESR1, BRCA1 | EBP 65/4885SIGMAR1 372/4885HRH3 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.